Uterine Cancer Treatment: Complete Clinical Guide, Benefits & Recovery

Clinical Overview: Understanding Uterine Cancer Treatment

Uterine Cancer Treatment represents a cornerstone clinical program at Spica Healthcare — Grover Hospital, Bathinda. Supervised directly by Dr. Neha Gupta (Director & Senior Medical Oncologist), this evidence-based pathway integrates sub-millimeter surgical precision, advanced intraoperative 3D navigation, ISO Class-100 Laminar Airflow surgical suites, and personalized accelerated rehabilitation to restore function, eliminate pain, and maximize long-term treatment longevity.

In South-Western Punjab and adjoining regions of Haryana and Rajasthan, patients frequently encounter delayed clinical diagnoses or generalized approaches that fail to address anatomical nuances. At Spica Healthcare, every patient undergoes rigorous digital staging, ensuring that surgical interventions or targeted medical therapies are customized to individual biomechanics and oncological requirements.

Clinical Indications: When is Uterine Cancer Treatment Recommended?

• Biopsy-proven endometrial adenocarcinoma, uterine serous carcinoma, or uterine carcinosarcoma.

• Postmenopausal women experiencing unexplained vaginal bleeding, staining, or discharge.

• Advanced or recurrent dMMR/MSI-H endometrial cancer requiring first-line Dostarlimab/Pembrolizumab immunotherapy.

• Lynch syndrome patients requiring intensive endometrial screening and risk-reducing surgery.

Step-by-Step Surgical & Clinical Pathway at Grover Hospital

Step 1: Endometrial Biopsy & Molecular Panel

Transvaginal ultrasound, endometrial biopsy, 3T Pelvic MRI, and MMR/p53/POLE molecular testing.

Step 2: Molecular Risk Stratification

Risk stratification guiding surgical staging vs upfront chemotherapy-immunotherapy.

Step 3: Surgical Resection or Immunotherapy

Laparoscopic total hysterectomy or outpatient immunotherapy infusions in Day Care suite.

Step 4: Adjuvant Care & Long-Term Follow-Up

Post-operative adjuvant brachytherapy if indicated and routine long-term surveillance.

Director's Signature Innovation: Comprehensive Multimodal Uterine & Endometrial Cancer Treatment

Dr. Neha Gupta coordinates comprehensive treatment for Endometrial and Uterine Cancers. Utilizing modern ProMisE / WHO molecular subtyping (POLE ultramutated, MSI-H/dMMR, MMRp/p53-abnormal), patients with early good-prognosis POLE cancers avoid unnecessary toxic radiation and chemotherapy, while advanced or recurrent dMMR/MSI-H uterine cancers achieve durable remissions with single-agent immunotherapy (Dostarlimab / Pembrolizumab - RUBY & GY018 protocols) or Lenvatinib + Pembrolizumab combination for p53/MMR-proficient tumors.

✔ WHO Molecular Subtyping: Replaces guesswork with 4 distinct biological prognostic groups

✔ First-Line Immunotherapy (Dostarlimab/Pembro): Slashes progression risk by over 70% in dMMR endometrial cancer

✔ Lenvatinib + Pembrolizumab: Highly effective targeted-IO combination for advanced MMR-proficient cancers

✔ Laparoscopic / Robotic Hysterectomy: Minimally invasive surgery with sentinel lymph node mapping

Recovery Timeline & Functional Milestones

Phase 1: Diagnostic Staging & Molecular Panel (Day 1 – 7)

Endometrial pipelle biopsy review, 3T Pelvic MRI, whole-body CT/PET, and MMR/p53/POLE molecular panel.

Phase 2: Minimally Invasive Surgical Phase (Month 1 – 2)

Laparoscopic/robotic total hysterectomy with bilateral salpingo-oophorectomy and sentinel node mapping.

Phase 3: Adjuvant Molecular-Directed Phase (Month 2 – 4)

Adjuvant vault brachytherapy, external radiation, or immunotherapy infusions based on molecular risk group.

Phase 4: Long-Term Remission & Survivorship (Month 6 – Long Term)

Regular gynaecological surveillance, pelvic exams, and long-term disease-free survivorship.

Frequently Asked Clinical Questions (FAQs)

What is the most common early warning sign of uterine cancer?

The hallmark warning sign of uterine (endometrial) cancer is abnormal vaginal bleeding or spotting in postmenopausal women (after menopause). In younger premenopausal women, it presents as heavy, prolonged, or irregular bleeding between periods. Any postmenopausal bleeding requires immediate ultrasound and endometrial biopsy.

Why is molecular genetic subtyping essential for uterine cancer?

Molecular testing divides endometrial cancer into 4 genetic groups (POLE, MSI-H/dMMR, p53-abnormal, and NSMP). Knowing your group tells Dr. Neha Gupta whether you can safely skip harsh chemotherapy (if POLE positive) or if you will have extraordinary cure rates with modern immunotherapy drugs like Dostarlimab.

Is Uterine Cancer Treatment cashless under Ayushman Bharat?

Yes, uterine cancer surgeries, laparoscopic hysterectomies, immunotherapy infusions, chemotherapy, and radiation at Grover Hospital Bathinda are covered 100% cashless under PM-JAY Ayushman Bharat and 30+ private TPAs.

100% Cashless Insurance & PM-JAY Ayushman Bharat Empanelment

At Spica Healthcare — Grover Hospital Bathinda, Uterine Cancer Treatment is fully covered under the Government of India's PM-JAY Ayushman Bharat scheme and over 30+ leading private insurance TPAs. Our on-campus insurance coordinator handles all pre-authorization documentation directly with your insurance company, eliminating financial delays. Families can also share digital DICOM CDs and biopsy reports via WhatsApp (+91 95013 73003) for an urgent surgical review.